S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
Log in
ARCA:AIM

AIM ImmunoTech Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume701,905 shs
Market Capitalization$78.52 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.85
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has research agreement with the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd. to test its drug Ampligen as an adjuvant therapy for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.00 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone352 448 7797
Employees24

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$140,000.00
Book Value$1.48 per share

Profitability

Net Income$-9,530,000.00
Net Margins-6,823.39%

Miscellaneous

Market Cap$78.52 million
Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive AIM News and Ratings via Email

Sign-up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AIM ImmunoTech (ARCA:AIM) Frequently Asked Questions

What stocks does MarketBeat like better than AIM ImmunoTech?

Wall Street analysts have given AIM ImmunoTech a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AIM ImmunoTech wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of AIM ImmunoTech's key competitors?

Who are AIM ImmunoTech's key executives?

AIM ImmunoTech's management team includes the following people:
  • Mr. Thomas K. Equels, Exec. Vice Chairman, CEO & Pres (Age 67, Pay $780.84k)
  • Ms. Ellen M. Lintal, CFO & Chief Accounting Officer (Age 61, Pay $177.32k)
  • Mr. Peter W. Rodino III, Esq., J.D., COO, Exec. Director of Gov.al Relations, Gen. Counsel & Sec. (Age 69, Pay $379.04k)
  • Dr. David R. Strayer, Chief Scientific Officer & Medical Director (Age 74)
  • Ann Marie E. Coverly, Director of Admin. & HR and Deputy Investor Relations Coordinator
  • Dr. Carol A. Smith, Chief Manufacturing Officer & Deputy Chief Scientific Officer (Age 69)
  • Julie Mierau, Controller
  • Dr. Ralph Christopher Cavalli, VP of QC & Manufacturing (Age 62)

What is AIM ImmunoTech's stock symbol?

AIM ImmunoTech trades on the ARCA under the ticker symbol "AIM."

How do I buy shares of AIM ImmunoTech?

Shares of AIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is AIM ImmunoTech?

AIM ImmunoTech has a market capitalization of $0.00 and generates $140,000.00 in revenue each year. AIM ImmunoTech employs 24 workers across the globe.

What is AIM ImmunoTech's official website?

The official website for AIM ImmunoTech is www.aimimmuno.com.

How can I contact AIM ImmunoTech?

AIM ImmunoTech's mailing address is 2117 SW HIGHWAY 484, OCALA FL, 34473. The company can be reached via phone at 352 448 7797 or via email at [email protected]

This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.